This consultation represents a pivotal moment for stakeholders across the biotech and health innovation landscapes. Its primary objective is to develop a comprehensive and future-proof regulatory framework that supports the sustainable growth of biotechnology in Europe. The Act aims to foster innovation, ensure public trust, and promote the global competitiveness of European biotech companies.
One of the five key areas highlighted in the consultation is the integration of artificial intelligence (AI) into the biotechnology ecosystem. This strategic focus includes:
- Enhancing access to data and high-performance computing resources, enabling researchers and developers to work with larger datasets and more complex models;
- Leveraging AI tools to accelerate research and innovation, particularly in drug discovery, diagnostics, and personalized medicine;
- Establishing safeguards to ensure the safe, ethical, and responsible use of biotechnology and AI, fostering public confidence and aligning with EU values.
This consultation provides a unique opportunity for industry experts, researchers, companies, regulatory professionals, and civil society to contribute their insights and shape a regulation that could significantly impact the future of health technologies and life sciences in the EU.
As a consultancy firm specialized in regulatory affairs and emerging technologies, Asphalion fully supports initiatives that position artificial intelligence as a key driver of innovation and competitiveness in the healthcare sector. We believe that a well-designed regulatory framework can empower safe, effective, and rapid advancements in biotechnology.
Deadline for contributions: June 4
Stakeholders are encouraged to review the consultation details and submit their feedback before the deadline.
More information and access to the consultation can be found here: EU CONSULTATION
Contact us for further information: [email protected]
